ProQR Therapeutics N.V.
corporate_fare Company Profile
ProQR Therapeutics N.V. (NASDAQ:PRQR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for PRQR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for PRQR spans 6-K, 4, SCHEDULE 13D/A, 424B5.
Recent high-impact activity:
- ProQR Doses First Patient in Phase 1 Study for Next-Gen Liver Disease Drug AX-0811
- ProQR Q2 Revenue Doubles to €8.76M, Beats Consensus by 91%
- ProQR Reports Q2 Results, Announces First Clinical Validation of Axiomer™ RNA Editing Platform
- ProQR's Q2 2026 Update: Cash Runway to Mid-2028 and a Pipeline of Clinical Milestones
- CEO Daniel de Boer Buys $354K of ProQR Stock at $1.77
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for PRQR, detected from its recent SEC filings · based on capital-structure filings through 2026-07-15.
Capital Raise Finalized · Significant Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
PRQR files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.